Investment Rating - The report initiates coverage with a "Buy" rating for the company [5][7]. Core Insights - The company focuses on the research and development of innovative drugs for autoimmune diseases and has established strategic partnerships with various pharmaceutical companies, indicating strong potential for future product sales and continued pipeline licensing opportunities [2][5]. - The company has a comprehensive pipeline targeting four major autoimmune diseases, with a priority on skin diseases, currently holding one approved product, nine in development, and over twenty IND approved projects [5][7]. - The global autoimmune drug market is projected to reach USD 176.7 billion by 2030, with biologics' market share expected to increase from 72.8% in 2022 to 82.1% by 2030 [5][7]. Financial Summary - Revenue projections for the company are as follows: - 2024: RMB 159 million - 2025: RMB 687 million (up 333%) - 2026: RMB 594 million (down 14%) - 2027: RMB 755 million (up 27%) [6][8]. - The company is expected to achieve EPS of RMB 0.61, 0.42, and 0.83 for the years 2025, 2026, and 2027 respectively [5][7]. - The target price is set at HKD 30.15 based on DCF valuation methods [5][7]. Business Segmentation - The company's core business revenue is divided into three segments: - Revenue from licensing agreements - Research and development services - Drug sales - Forecasted revenue breakdown for 2024-2027 indicates significant growth in licensing income, with a projected increase from RMB 100.94 million in 2024 to RMB 560 million in 2027 [8].

Core Viewpoint - The recent mid-year performance announcement from Qianxin Biotech shows a significant revenue increase, indicating strong market confidence and the company's successful internationalization strategy [1][4]. Financial Performance - For the first half of 2025, Qianxin Biotech reported revenue of 206 million yuan, a year-on-year increase of 359.69% [1][4]. - The company's loss narrowed significantly to 30.93 million yuan, a reduction of 83.11% compared to the previous year [4]. - Cash and cash equivalents reached 559 million yuan, indicating a healthy cash flow situation [4]. Capital Market Recognition - TruMed Health Innovation Fund LP completed a rapid subscription for 5 million shares of Qianxin Biotech, raising 99 million HKD, reflecting strong institutional confidence in the company's long-term value [3][4]. - The funds raised will be used for debt repayment, accelerating the development of new pipelines, and supplementing working capital [3]. Product Development and Pipeline - Qianxin Biotech has developed a differentiated product pipeline targeting various autoimmune and allergic diseases, including the recently approved biosimilar drug, QX001S (赛乐信®) [2]. - The company has entered into an overseas NewCo transaction with Caldera Therapeutics, receiving an upfront payment of 10 million USD and a 24.88% equity stake, marking a significant step in its internationalization efforts [2]. Globalization Strategy - The company aims to accelerate its overseas business development, with a target of completing two projects for international markets in 2025 [5]. - Qianxin Biotech plans to collaborate with top-tier international pharmaceutical companies for "first in class" or "best in class" products, while also targeting markets in countries along the Belt and Road Initiative [5][6]. Market Context - The global autoimmune market is projected to grow from approximately 107.9 billion USD in 2024 to 137.59 billion USD by 2033, indicating a significant opportunity for growth in this sector [1][2]. - The international environment necessitates that Chinese innovative pharmaceutical companies pursue globalization as a survival strategy, with strong demand for high-quality innovative drugs in the European and American markets [6].